Montinex Chewable Tablet 5 mg

Montinex (Montelukast Sodium) is a 5 mg tablet manufactured by Beacon Pharmaceuticals PLC. Priced at ৳9.00 per unit, this leukotriene receptor antagonist helps manage respiratory conditions. Available in strips of 10 tablets (৳90.00) and packs of 30 tablets (৳270.00), it requires storage below 30°C, protected from light and moisture.

Indications include:

• Preventing asthma attacks
• Treating exercise-induced bronchoconstriction
• Managing seasonal/perennial allergic rhinitis

As a chewable tablet, Montinex blocks cysteinyl leukotriene receptors, reducing airway inflammation and allergic responses.

Dosage varies by age:

• Adults: 10 mg daily
• Children (6-14 years): 5 mg daily
• Infants (6 months-5 years): 4 mg daily

Take 2 hours before exercise for bronchoconstriction. Can be consumed with/without food under medical supervision.

Common side effects:

• Headache, diarrhea, nausea
• Upper respiratory infections

Rare risks:

• Neuropsychiatric symptoms
• Liver dysfunction
• Allergic reactions

Monitor for unusual behavioral changes or physical symptoms.

Use cautiously during pregnancy/lactation. No major food interactions reported. Overdose management focuses on symptom relief and clinical monitoring. Consult doctors when using with NSAIDs, antidepressants, or blood thinners.

Affordable at ৳9.00 per tablet, Montinex offers flexible packaging options. Always follow prescribed guidelines and report adverse effects promptly. Verify storage conditions to maintain efficacy.

Adults: 10 mg once daily. Pediatric: 5 mg (6-14 yrs), 4 mg (6mo-5 yrs). Take 2 hours before exercise for EIB. No dosage adjustment needed in renal/hepatic impairment.

Common: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.

Uncommon: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.

Rare: Angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor.

Pregnancy Category B. Use only if clearly needed. Excreted in breast milk – contraindicated during lactation.

Monitor for behavioral changes. Regular liver function tests recommended. Avoid abrupt discontinuation without medical advice.

No dosage adjustment in elderly. Use caution in severe hepatic impairment. Pediatric formulations require weight-based dosing.

There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of Montinex and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.